Latest Osteonecrosis of the jaw Stories

Quality of life can be significantly improved Inhibiting a protein involved in bone metabolism can delay the onset of the bone metastases which are common in men with a particular form of prostate cancer, a researcher will tell the 2011 European Multidisciplinary Cancer Congress today (Sunday). Professor Stéphane Oudard, Head of the Oncology Department at the Georges Pompidou Hospital, Paris, France, says that his team's research on the effects of the monoclonal antibody denosumab...

The Rottenstein Law Group, which represents clients with claims of harm resulting from use of the drug Fosamax, is paying especial attention to the developments in the fifth case involving Fosamax and a painful condition known as osteonecrosis of the jaw to go to trial, now underway. New York, NY (PRWEB) September 19, 2011 On September 8, in Secrest v. Merck—a so-called bellwether lawsuit of the many that were consolidated for pre-trial purposes in In Re: Fosamax (Alendronate...

THOUSAND OAKS, Calif., Sept. 19, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved two new indications for Prolia® (denosumab) as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer and as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer. In patients...

THOUSAND OAKS, Calif., Sept. 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new long-term data showing that Prolia® (denosumab) treatment for up to eight years in postmenopausal women with low bone mass or osteoporosis was associated with a continued increase in bone mineral density (BMD), an important determinant of bone strength, and a persistent reduction in markers of bone turnover. The data were presented at the annual meeting of the American Society for Bone and...

The US Drug Watchdog is dramatically expanding its national initiative involving the osteoporosis drug called Fosamax, and women who may have suffered out of the blue fractures to their femur, or thigh bone. According to the FDA, "typically these fractures occurred after using Fosamax for five years, or more." The US Drug Watchdog says, "In the instance of Fosamax, we are talking about women, whose leg simply broke. They did not fall, they did not run into something, their...

The Rottenstein Law Group, which represents clients with claims of harm resulting from use of the drug Fosamax, notes a recent possible setback for Canadians who have suffered harm after taking Fosamax. New York, NY (PRWEB) September 05, 2011 In early June 2011, the Quebec Superior Court dismissed a motion seeking authorization of a class action against Merck Canada Inc and Merck & Co Inc on behalf of all natural persons in Quebec who had purchased or taken Fosamax. The petitioner in...

THOUSAND OAKS, Calif., Aug. 25, 2011 /PRNewswire/ -- Emmy® and Tony® award-winning actress Blythe Danner and Amgen (NASDAQ:AMGN) today launch Act 2 Reduce Fractures(TM), an educational campaign for women with postmenopausal osteoporosis at increased risk for fractures. Earlier this year, Danner was diagnosed with postmenopausal osteoporosis at increased risk for fractures and wants to encourage women like her to educate themselves, take action and speak to their doctors to learn all...

The Rottenstein Law Group, which represents clients with claims stemming from the severe side effects of the drug Fosamax, is eagerly awaiting the report of an FDA panel being convened in September to discuss Fosamax, and specifically whether the drug increases incidence of throat cancer. New York, NY (PRWEB) July 25, 2011 According to an article published by Bloomberg on July 21, in advance of an advisory panel meeting on September 9 to discuss the long-term safety of drugs used to...

THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. This approval of XGEVA applies to all 27 European Union (EU) member states. The EC also granted XGEVA an additional...

To fully optimize a drug therapy for osteoporosis and low bone mineral density (BMD), patients should maintain vitamin D levels above the limits recently recommended by the Institute of Medicine (IOM), according to a new study by researchers from Hospital for Special Surgery in New York. The study will be presented at the Endocrine Society's Annual Meeting in Boston, June 4-7.The study demonstrated that maintaining a circulating vitamin D level above 33 ng/ml is associated with a seven-fold...